NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Gmax Biopharm

Gmax Biopharm

Private
HangzhouHealthcare & Life Scienceshttps://gmaxbiopharm.com/

Last Round

Series C

Mar 9, 2021

Est. Valuation

$80.52M

Total Funding Raised

$92.22M

Company Overview

Gmax Biopharm is a biopharmaceutical company that develops innovative therapeutic monoclonal antibodies targeting G-protein coupled receptors (GPCRs) for the treatment of cardiovascular, metabolic, and cancer-related diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

antibody therapeuticsGPCRG-protein coupled receptorsmonoclonal antibodybispecific antibodydrug discoverybiotechclinical-stage biopharmaantibody engineeringmultispecific antibodyGLP-1R agonistdrug licensingbiologicstherapeutic pipelineco-development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Gmax Biopharm Comparables

Compare Gmax Biopharm with similar companies based on industry and business-model similarity.

Gmax Biopharm comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
QL Biopharm
87%
Zhejiang Doer Biologics
86%
Sino Biopharmaceutical
80%

Gmax Biopharm Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CMar 9, 2021
Series BJan 22, 2017
Series ADec 28, 2014
AngelSep 1, 2010

Gmax Biopharm Investors

Notable investors and investment history

Gmax Biopharm investors
InvestorRounds
China Merchants GroupSeries C
Zhongyuan CapitalSeries C
LechuanghuiSeries A
Efung CapitalSeries B
Cowin CapitalSeries C

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 2, 2026

    Monthly visitors grew 3197% MoM, reaching 5.3K.

  • Jun 1, 2025

    Monthly visitors increased 68% MoM, reaching 1K.

Gmax Biopharm Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Gmax Biopharm Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Gmax Biopharm's valuation, stock price, and market status.

Firmographic Details

HeadquartersHangzhou
Employee Range18
Year Founded2010
Last FundingMar 9, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.